United Therapeutics Co. (NASDAQ:UTHR) Stock Holdings Cut by Swiss National Bank

Swiss National Bank lessened its position in United Therapeutics Co. (NASDAQ:UTHR) by 2.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 146,755 shares of the biotechnology company’s stock after selling 3,900 shares during the period. Swiss National Bank owned approximately 0.31% of United Therapeutics worth $32,270,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Fisher Asset Management LLC lifted its stake in United Therapeutics by 3.1% during the fourth quarter. Fisher Asset Management LLC now owns 3,731 shares of the biotechnology company’s stock valued at $820,000 after purchasing an additional 112 shares during the last quarter. First Trust Direct Indexing L.P. lifted its position in shares of United Therapeutics by 14.0% during the 4th quarter. First Trust Direct Indexing L.P. now owns 1,527 shares of the biotechnology company’s stock valued at $336,000 after acquiring an additional 187 shares during the last quarter. New York Life Investment Management LLC boosted its stake in shares of United Therapeutics by 4.4% during the 4th quarter. New York Life Investment Management LLC now owns 5,644 shares of the biotechnology company’s stock worth $1,241,000 after acquiring an additional 238 shares in the last quarter. Victory Capital Management Inc. grew its holdings in shares of United Therapeutics by 309.7% in the 4th quarter. Victory Capital Management Inc. now owns 134,162 shares of the biotechnology company’s stock worth $29,501,000 after acquiring an additional 101,419 shares during the last quarter. Finally, Jackson Creek Investment Advisors LLC acquired a new stake in shares of United Therapeutics during the fourth quarter worth $683,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. HC Wainwright reissued a “buy” rating and issued a $300.00 price target on shares of United Therapeutics in a research note on Thursday, May 2nd. SVB Leerink assumed coverage on shares of United Therapeutics in a report on Monday, February 5th. They set an “outperform” rating and a $330.00 price target on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of United Therapeutics in a research note on Monday, February 5th. Oppenheimer boosted their target price on shares of United Therapeutics from $375.00 to $400.00 and gave the company an “outperform” rating in a research note on Thursday, May 2nd. Finally, StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, April 11th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to MarketBeat, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $308.78.

Insider Activity at United Therapeutics

In other United Therapeutics news, CEO Martine A. Rothblatt sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total value of $3,548,850.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares of the company’s stock, valued at $30,756.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other United Therapeutics news, CEO Martine A. Rothblatt sold 14,125 shares of the company’s stock in a transaction that occurred on Thursday, March 28th. The stock was sold at an average price of $236.18, for a total transaction of $3,336,042.50. Following the completion of the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,703.40. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Martine A. Rothblatt sold 15,000 shares of United Therapeutics stock in a transaction that occurred on Tuesday, March 19th. The shares were sold at an average price of $236.59, for a total transaction of $3,548,850.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at approximately $30,756.70. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 147,630 shares of company stock valued at $35,089,803. 12.50% of the stock is currently owned by corporate insiders.

United Therapeutics Trading Up 2.2 %

NASDAQ UTHR opened at $266.22 on Wednesday. The company has a market capitalization of $11.81 billion, a PE ratio of 12.59 and a beta of 0.54. United Therapeutics Co. has a 1-year low of $204.44 and a 1-year high of $266.65. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The firm’s fifty day simple moving average is $238.38 and its 200-day simple moving average is $229.88.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, topping the consensus estimate of $5.63 by $0.54. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. United Therapeutics had a return on equity of 18.72% and a net margin of 42.05%. The business’s revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $4.86 EPS. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 23.88 earnings per share for the current fiscal year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.